Adaptimmune Therapeutics (ADAP) News Today $0.56 -0.02 (-3.45%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.56 +0.00 (+0.45%) As of 02/21/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 29.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,819,095 shares of the biotechnoloFebruary 19 at 4:30 AM | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest UpdateAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,880,000 shares, an increase of 19.4% from the January 15th total of 5,760,000 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is presently 3.4 days.February 15, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) and Neumora Therapeutics (NASDAQ:NMRA) Head to Head ReviewFebruary 15, 2025 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)February 11, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Crosses Below 50-Day Moving Average - Should You Sell?Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50 Day Moving Average - Here's What HappenedFebruary 11, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Significant Increase in Short InterestAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is currently 2.6 days.February 2, 2025 | marketbeat.comGuggenheim Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)January 30, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Below 50-Day Moving Average - Here's What HappenedAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below Fifty Day Moving Average - Time to Sell?January 28, 2025 | marketbeat.comH.C. Wainwright Remains a Buy on Adaptimmune Therapeutics (ADAP)January 23, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years agoJanuary 22, 2025 | uk.finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Increase in Short InterestAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 2.6 days.January 19, 2025 | marketbeat.comAdaptimmune therapeutics COO sells shares worth $3,243January 18, 2025 | msn.comAdaptimmune therapeutics' chief medical officer sells $3,243 in stockJanuary 18, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Danaher (DHR)January 14, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)January 12, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Below Fifty Day Moving Average - Here's What HappenedAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50-Day Moving Average - What's Next?January 9, 2025 | marketbeat.comPhilly’s year in biopharma: a look back at 2024December 31, 2024 | msn.com2024 in Review: 'Biotech winter' costs Greater Philadelphia hundreds of additional life sciences jobsDecember 29, 2024 | bizjournals.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 24.7% in DecemberAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 5,060,000 shares, a decrease of 24.7% from the November 30th total of 6,720,000 shares. Based on an average trading volume of 1,840,000 shares, the short-interest ratio is currently 2.8 days.December 28, 2024 | marketbeat.comAdaptimmune Therapeutics Announces Key Leadership ChangesDecember 19, 2024 | markets.businessinsider.comAdaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlookDecember 19, 2024 | uk.investing.comEuropean Equities Traded in the US as American Depositary Rise in Thursday TradingDecember 5, 2024 | msn.comMatrix Capital Management Company LP Trims Stock Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Matrix Capital Management Company LP lowered its position in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 3.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 37,681,515 shares of the biotechnology company's stock after selling 1,292,670 shaDecember 4, 2024 | marketbeat.comAdaptimmune Therapeutics: Strategic Restructuring and Promising Developments Drive ‘Buy’ RatingNovember 27, 2024 | markets.businessinsider.comDemystifying Adaptimmune Therapeutics: Insights From 4 Analyst ReviewsNovember 27, 2024 | benzinga.comPromising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial PositionNovember 19, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Rise in Monday TradingNovember 18, 2024 | msn.comEquities Analysts Offer Predictions for ADAP FY2024 EarningsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He now forecasts that the biotechnology company willNovember 18, 2024 | marketbeat.comAdaptimmune Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comAdaptimmune nears second sarcoma approval as Phase II trial hits endpointsNovember 16, 2024 | msn.comAdaptimmune price target lowered to $3 from $4 at GuggenheimNovember 15, 2024 | markets.businessinsider.comAdaptimmune Therapeutics: Strategic Realignment and Cautious Optimism for Future GrowthNovember 15, 2024 | markets.businessinsider.comGuggenheim Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock PriceGuggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday.November 15, 2024 | marketbeat.comQ1 Earnings Forecast for ADAP Issued By HC WainwrightAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnoloNovember 15, 2024 | marketbeat.comPhiladelphia life sciences firm reducing headcount by 33%November 15, 2024 | bizjournals.comAdaptimmune price target lowered to $3.50 from $4 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comScotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)November 14, 2024 | markets.businessinsider.comAdaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy RatingNovember 14, 2024 | markets.businessinsider.comAdaptimmune trading halted, news pendingNovember 14, 2024 | markets.businessinsider.comAdaptimmune’s Strategic Shift and Financial UpdateNovember 14, 2024 | markets.businessinsider.comAdaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comBaillie Gifford & Co. Increases Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. increased its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 10.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,775,860 shares of the biotNovember 13, 2024 | marketbeat.comAn Overview of Adaptimmune Therapeutics's EarningsNovember 12, 2024 | benzinga.comAdaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on WednesdayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 9, 2024 | marketbeat.comAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Scientific and Medical Conferences this November and DecemberNovember 5, 2024 | finanznachrichten.deADAP Adaptimmune Therapeutics plcOctober 18, 2024 | seekingalpha.comOTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCROctober 10, 2024 | msn.comLong Focus Capital Management LLC Has $12.04 Million Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Long Focus Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 15.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,346,September 27, 2024 | marketbeat.comAdaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutionsSeptember 25, 2024 | finance.yahoo.comAdaptimmune's T-Cell Therapy Journey: A Small Market, Big AmbitionsSeptember 12, 2024 | seekingalpha.com Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼1.220.60▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼32▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC News RAPP News SEPN News PGEN News STOK News CGEM News AUTL News VALN News XERS News TECX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts